Of course, were still early: Most studies are small or preclinical Larger clinical trials are needed Access, cost, and safety must be considered But this could represent a real shift in how we think about treating addiction not just as a behavioral condition, but as one deeply tied to metabolic and brain pathways
In the SURMOUNT-1 trial, adults taking injectable tirzepatide lost an average of about 15% with the 5 mg dose, 19.5% with the 10 mg dose, and 20.9% to 22.5% with the highest 15 mg dose after 72 weeks
Business Type Supplier, Trading Company, Wholesaler, Retailer Employee Count 5 Establishment 2022 Working Days To GST NO 10BTYPG3426J1ZL Payment Mode Cash Related Products Explore Related Categories More Products From This Seller Seller Details GST - 10BTYPG3426J1ZL Patna, Bihar Proprietor Mr
J Neuroinflammation 16
Retrieved from Drucker, D